Journal article

Authors list: Franke, Friedrich Christian; Damek, Adrian; Steglich, Jonas; Kurch, Lars; Hasenclever, Dirk; Georgi, Thomas W.; Wohlgemuth, Walther Alexander; Mauz-Koerholz, Christine; Koerholz, Dieter; Kluge, Regine; Landman-Parker, Judith; Wallace, William Hamish; Fossa, Alexander; Vordermark, Dirk; Karlen, Jonas; Fernandez-Teijeiro, Ana; Cepelova, Michaela; Klekawka, Tomasz; Attarbaschi, Andishe; Ceppi, Francesco; Hraskova, Andrea; Uyttebroeck, Anne; Beishuizen, Auke; Dieckmann, Karin; Leblanc, Thierry; Moellers, Martin; Buerke, Boris; Stoevesandt, Dietrich

Publication year: 2023

Journal: Pediatric Blood & Cancer

Volume number: 70

Issue number: 8

ISSN: 1545-5009

eISSN: 1545-5017

Open access status: Hybrid

DOI Link: https://doi.org/10.1002/pbc.30421

Publisher: Wiley

Abstract: 
BackgroundRebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemotherapy (CTX) or radiotherapy, with an incidence between 44% and 67.7% in pediatric lymphoma. Misinterpretation of RTH and thymic lymphoma relapse (LR) may lead to unnecessary diagnostic procedures including invasive biopsies or treatment intensification. The aim of this study was to identify parameters that differentiate between RTH and thymic LR in the anterior mediastinum. MethodsAfter completion of CTX, we analyzed computed tomographies (CTs) and magnetic resonance images (MRIs) of 291 patients with classical Hodgkin lymphoma (CHL) and adequate imaging available from the European Network for Pediatric Hodgkin lymphoma C1 trial. In all patients with biopsy-proven LR, an additional fluorodeoxyglucose (FDG)-positron emission tomography (PET)-CT was assessed. Structure and morphologic configuration in addition to calcifications and presence of multiple masses in the thymic region and signs of extrathymic LR were evaluated. ResultsAfter CTX, a significant volume increase of new or growing masses in the thymic space occurred in 133 of 291 patients. Without biopsy, only 98 patients could be identified as RTH or LR. No single finding related to thymic regrowth allowed differentiation between RTH and LR. However, the vast majority of cases with thymic LR presented with additional increasing tumor masses (33/34). All RTH patients (64/64) presented with isolated thymic growth. ConclusionIsolated thymic LR is very uncommon. CHL relapse should be suspected when increasing tumor masses are present in distant sites outside of the thymic area. Conversely, if regrowth of lymphoma in other sites can be excluded, isolated thymic mass after CTX likely represents RTH.

Harvard Citation style: Franke, F., Damek, A., Steglich, J., Kurch, L., Hasenclever, D., Georgi, T., et al. (2023) Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma, Pediatric Blood & Cancer, 70(8). https://doi.org/10.1002/pbc.30421

APA Citation style: Franke, F., Damek, A., Steglich, J., Kurch, L., Hasenclever, D., Georgi, T., Wohlgemuth, W., Mauz-Koerholz, C., Koerholz, D., Kluge, R., Landman-Parker, J., Wallace, W., Fossa, A., Vordermark, D., Karlen, J., Fernandez-Teijeiro, A., Cepelova, M., Klekawka, T., Attarbaschi, A., ...Stoevesandt, D. (2023). Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma. Pediatric Blood & Cancer. 70(8). https://doi.org/10.1002/pbc.30421